Efficacy and safety of regorafenib alone or in combinations in the second-line setting for advanced hepatocellular carcinoma: A multicenter real-world study.

被引：0
|
作者：
Zhang, Wei
Zhao, Yanrong
Ma, Guixiang
Zhang, Yu
Guo, Yuan
Chen, Zhong
机构：
[1] Nantong Univ, Dept Hepatobiliary & Pancreat Surg, Affiliated Hosp, Nantong, Peoples R China
[2] Qingdao Univ, Affiliated Hosp, Liver Dis Ctr, Qingdao, Peoples R China
[3] Siyang Hosp, Dept Oncol, Suqian, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16172
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of regorafenib alone or in combinations for advanced hepatocellular carcinoma: A multicenter real-world study.
    Zhu, Haidong
    Zhu, Xiaoli
    Song, Yusheng
    Wang, Qi
    Wu, Jianbing
    Xu, Hao
    Teng, Gaojun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16122 - E16122
  • [2] Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world study
    Qiao, Liang
    He, Wei
    Wang, Guoying
    Chen, Huanwei
    Huang, Fuxi
    Zhang, Bo
    Qiu, Yuxiong
    Liu, Shaoru
    Huang, Zhenkun
    Yuan, Yichuan
    Qiu, Jiliang
    Yuan, Yunfei
    Li, Binkui
    CANCER MEDICINE, 2024, 13 (09):
  • [3] Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
    Li, B-K.
    Yuan, Y.
    Qiao, L.
    He, W.
    Wang, G.
    Chen, H.
    Zhang, B.
    Fuxi, H.
    Qiu, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S596 - S596
  • [4] Efficacy and safety of second-line regorafenib after sorafenib or lenvatinib first line in patients with unresectable hepatocellular carcinoma: A real-world study.
    Xue, Feng
    Zhai, Jian
    Liu, Jianwei
    Fu, Zhigang
    Sun, Yanfu
    Ge, Ruiliang
    Bai, Shilei
    Li, Xiaowei
    Wang, Kui
    Qu, Zengqiang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16125 - E16125
  • [5] A real-world study of TACE combined with regorafenib as a second-line treatment for advanced hepatocellular carcinoma
    Liu, Shaoxing
    Gao, Song
    Guo, Jianhai
    Kou, Fuxin
    Zhang, Xin
    Liu, Baojiang
    Feng, Aiwei
    Wang, Xiaodong
    Chen, Hui
    Zhu, Xu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Efficacy and safety of regorafenib and/or immune checkpoint inhibitors as a second-line therapy for advanced hepatocellular carcinoma: A real-world study from a single center.
    Liu, Songtao
    Huang, Xueying
    Chen, Jingjing
    Wei, Qiaoxin
    Liu, Mei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice
    Liu, Kan
    Wu, Jianbing
    Xu, Yongkang
    Li, Dan
    Huang, Shenlang
    Mao, Ye
    ONCOTARGETS AND THERAPY, 2022, 15 : 1079 - 1094
  • [8] Efficacy and safety of TACE combined with ablation and regorafenib for unresectable hepatocellular carcinoma: A real-world study.
    Xiong, Yiqi
    Gao, WenFeng
    Long, Jiang
    Hu, CaiXia
    Yuan, ChunWang
    Sun, Yu
    Shi, QinSheng
    Sun, Bin
    Zhang, YingHua
    Cui, XiongWei
    Hao, MeiJun
    Li, Jianjun
    Zhang, Yonghong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Regorafenib combined with transarterial chemoembolization and PD-1 antibody as a second-line therapy for hepatocellular carcinoma: A real-world study.
    Pan, Tao
    Huang, Mingsheng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16167 - E16167
  • [10] The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting
    Obi, Shuntaro
    Sato, Takahisa
    Sato, Shinpei
    Kanda, Miho
    Tokudome, Yuta
    Kojima, Yuichiro
    Suzuki, Yoji
    Hosoda, Kenji
    Kawai, Toshihiro
    Kondo, Yuji
    Isomura, Yoshihiro
    Ohyama, Hiroshi
    Nakagomi, Keiko
    Ashizawa, Hiroshi
    Miura, Yuko
    Amano, Hiroyuki
    Mochizuki, Hitoshi
    Omata, Masao
    HEPATOLOGY INTERNATIONAL, 2019, 13 (02) : 199 - 204
12345